DARU Journal of Pharmaceutical Sciences最新文献

{"title":"A synthetic curcumin-like diarylpentanoid analog inhibits rhinovirus infection in H1 hela cells via multiple antiviral mechanisms.","authors":"Kong Yen Liew, Hui-Yee Chee, Faridah Abas, Sze Wei Leong, Hanis Hazeera Harith, Daud Ahmad Israf, Mohd Roslan Sulaiman, Chau Ling Tham","doi":"10.1007/s40199-024-00542-x","DOIUrl":"10.1007/s40199-024-00542-x","url":null,"abstract":"<p><strong>Background: </strong>Rhinovirus (RV) infection is a major cause of common colds and asthma exacerbations, with no antiviral drug available. Curcumin exhibits broad-spectrum antiviral activities, but its therapeutic effect is limited by a poor pharmacokinetics profile. Curcumin-like diarylpentanoid analogs, particularly 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDHBC) and 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD), have better solubility and stability compared to curcumin.</p><p><strong>Objectives: </strong>Therefore, this study aims to evaluate and compare the antiviral effects of curcumin, BDHBC, and DHHPD in an in vitro model of RV infection.</p><p><strong>Methods: </strong>The inhibitory effects on RV-16 infection in H1 HeLa cells were assessed using cytopathic effect (CPE) reduction assay, virus yield reduction assay, RT-qPCR, and Western blot. Antiviral effects in different modes of treatment (pre-, co-, and post-treatment) were also compared. Additionally, intercellular adhesion molecule 1 (ICAM-1) expression, RV binding, and infectivity were measured with Western blot, flow cytometry, and virucidal assay, respectively.</p><p><strong>Results: </strong>When used as a post-treatment, BDHBC (EC₅₀: 4.19 µM; SI: 8.32) demonstrated stronger antiviral potential on RV-16 compared to DHHPD (EC₅₀: 18.24 µM; SI: 1.82) and curcumin (less than 50% inhibition). BDHBC also showed the strongest inhibitory effect on RV-induced CPE, virus yield, vRNA, and viral proteins (P1, VP0, and VP2). Furthermore, BDHBC pre-treatment has a prophylactic effect against RV infection, which was attributed to reduced basal expression of ICAM-1. However, it did not affect virus binding, but exerted virucidal activity on RV-16, contributing to its antiviral effect during co-treatment.</p><p><strong>Conclusion: </strong>BDHBC exhibits multiple antiviral mechanisms against RV infection and thus could be a potential antiviral agent for RV.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"729-744"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the treatment of iron deficiency anemia on chronic drug-resistant cough: a rare case report.","authors":"Fatemeh Akbari, Lale Vahedi Larijani, Ehsan Rajabi Visroodi, Bahareh Hakiminia","doi":"10.1007/s40199-024-00522-1","DOIUrl":"10.1007/s40199-024-00522-1","url":null,"abstract":"<p><strong>Background: </strong>A persistent difficult-to-treat cough can be exhausting. Iron is an essential element that plays an important role in regulating the production of pro-inflammatory cytokines, and its deficiency may potentiate airway inflammation and dysfunction. There is a paucity of data regarding a link between iron deficiency (ID) and idiopathic cough.</p><p><strong>Objectives: </strong>In this study, a case of persistent non-productive cough, which was unresponsive to targeted treatment approaches but responsive to iron therapy, is reported.</p><p><strong>Methods: </strong>A 53-year-old woman came to a medical clinic with complaints of a chronic and progressive non-productive cough. She underwent a complete clinical and paraclinical evaluation.</p><p><strong>Results: </strong>Her vital signs were stable and no abnormalities were found on the physical examination. The results of the spirometry and chest radiography were unremarkable. The laboratory test indicated hypochromic microcytic anemia, with a hemoglobin value of 9.6 g/dL. Her cough was resolved after treatment of iron-deficiency anemia with an oral nutraceutical capsule containing 28 mg of elemental iron (as ferrous bis-glycinate) plus folic acid, vitamin B12, and vitamin C, once daily for six months.</p><p><strong>Conclusion: </strong>In the case of unexplained chronic cough, resistant to targeted therapies, investigation and treatment of ID may contribute to the resolution of cough.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"967-971"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relieving postherpetic neuralgia pain via gabapentin-loaded bigels as an auspicious topical drug delivery system.","authors":"Wessam H Abd-Elsalam, Abdulaziz Mohsen Al-Mahallawi, Amal Makhlouf","doi":"10.1007/s40199-024-00541-y","DOIUrl":"10.1007/s40199-024-00541-y","url":null,"abstract":"<p><strong>Background: </strong>Over the past decades, a substantial portion of the population worldwide has been infected with varicella zoster and most cases developed shingles. Unfortunately, shingles is usually accompanied by postherpetic neuralgia, which may persist for months to years after the resolution of the viral infection.</p><p><strong>Objectives: </strong>Gabapentin is an orally gamma-aminobutyric acid analogue approved by the Food and Drug Administration to manage shingles postherpetic neuralgia. However, gabapentin shows nonlinear pharmacokinetics, with variable absorption and bioavailability along with its short half-life and long side effects that may include dizziness and somnolence, which calls for an appropriate topical dosage form. Bigels are unique semisolid dosage forms with boosted penetrability and satisfactory hydrophilic texture.</p><p><strong>Methods: </strong>The current work pointed to formulating gabapentin-loaded bigels for the treatment of postherpetic neuralgia, where the analysis and optimization of design were performed via Design-Expert®.</p><p><strong>Results and conclusions: </strong>The selected bigel (F5), incorporating 400 mg Span 60, 1000 mg Tween 80, and 1000 mg Transcutol, displayed spherical nanosized particles with acceptable viscosity and spreadability. Subsequent topical application of the selected bigel on the skin of Wistar rats, F5, demonstrated a boosted accumulation of gabapentin in the skin similar to PLO gel but superior to the drug solution. Furthermore, a histopathological study demonstrated the biosafety of the selected bigel when applied topically. Accordingly, gabapentin-loaded bigel would be considered a potentially topical dosage form for the delivery of gabapentin for the management of postherpetic neuralgia.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"705-714"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater.","authors":"Azra Takhvar, Somaye Akbari, Effat Souri, Reza Ahmadkhaniha, Ali Morsali, Mohammad Reza Khoshayand, Mohsen Amini, Alireza Taheri","doi":"10.1007/s40199-024-00531-0","DOIUrl":"10.1007/s40199-024-00531-0","url":null,"abstract":"<p><strong>Background: </strong>Nilotinib (NIL) is a prescription medication employed in the treatment of specific types of leukemia, namely chronic myelogenous leukemia (CML). The determination of NIL levels in patients undergoing treatment for CML is of paramount importance for effective management of treatment and toxicity. Also, monitoring and controlling its level in wastewater sources could help scientists to identify potential hotspots of contamination and take appropriate measures to mitigate their impact on the environment and public health.</p><p><strong>Objectives: </strong>This study presents a D-µ-SPE technique utilizing two MOFs as adsorbents for the efficient detection of nilotinib in plasma and wastewater samples for the first time.</p><p><strong>Methods: </strong>Two highly effective MOFs, MIL-101(Fe) and MIL-53(Al), were synthesized and applied as dispersive micro-solid phase extraction (D-µ-SPE) adsorbents for the extraction of nilotinib coupled with HPLC-UV in a short time of analysis. Experimental parameters affecting extraction efficacy such as adsorbent amount, ionic strength, pH value, adsorption-desorption time and type of elution solvent, were optimized.</p><p><strong>Results: </strong>Under optimal experimental conditions, the linear dynamic was achieved in the range of 0.25-5.00 µg/mL in human plasma and 0.01-0.20 µg/mL in wastewater. The extraction recovery was in the range of 89.18-91.53% and 94.39-99.60% for nilotinib and MIL-101(Fe) and also 91.22-97.35% and 98.14-100.78% for nilotinib and MIL-53(Al) from human plasma and wastewater respectively.</p><p><strong>Conclusion: </strong>HPLC-UV determination of nilotinib after the D-µ-SPE method showed acceptable accuracy and precision in both plasma and wastewater. In comparison between the two adsorbents, the extraction procedure was easier and faster with MIL-53(Al) as the adsorbent.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"617-630"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of the ethnomedicinal, phytochemical, and pharmacological properties of the Ferulago genus based on Structure-Activity Relationship (SAR) of coumarins.","authors":"Farid Dabaghian, Shokoufeh Aalinezhad, Alaleh Riazati Kesheh, Niloufar Azargashb, Ramin Ansari, Mohammad Reza Shams Ardekani, Seyed Ahmad Emami, Mahnaz Khanavi, Mohammad Reza Delnavazi","doi":"10.1007/s40199-024-00530-1","DOIUrl":"10.1007/s40199-024-00530-1","url":null,"abstract":"<p><strong>Background: </strong>The Ferluago W.D.J. Koch genus includes 48 accepted perennial herbs that are distributed in the Mediterranean region, Southeast Europe, Central and Middle East of Asia. These plants are widely used in folk and conventional medicine due to their biological benefits such as anti-microbial, anti-inflammatory, anti-cancer, and immunomodulatory properties. Conducting a comprehensive review based on the structure activity relationships (SARs) of the coumarins, which has not been previously documented, can lead to a better insight into the genus Ferulago and its beneficial therapeutic activities.</p><p><strong>Methods: </strong>This review covers literature from 1969 to 2023, were collected from various scientific electronic databases to review phytochemical, pharmacological, and ethnopharmacological data of Ferulago species, as well as latest information on the SAR of reported coumarins from this genus.</p><p><strong>Results: </strong>Phytochemical studies showed that the biological actions of this genus are mediated by the reported specialized metabolites, such as coumarins and flavonoids. Simple coumarins, prenylated coumarins, furanocoumarins, and pyranocoumarins are the largest subclasses of coumarins found in diverse Ferulago species, which have discussed the biological effects of them with a focus on the Structure-Activity Relationship (SAR). For example, prenylated coumarins have shown potential leishmanicidal and anti-neuropsychiatric effects when substituted with a prenyl group at the 7-hydroxy, as well as the C₆ and C₈ positions in their scaffold. Similarly, furanocoumarins exhibit varied biological activities such as anti-inflammatory, anti-proliferative, and anti-convulsant effects. Modifying substitutions at the C₅ and C₆ positions in furanocoumarins can enhance these activities.</p><p><strong>Conclusion: </strong>This study conducted a comprehensive review of all available information on the phytochemical and pharmacological characteristics of Ferulago species. Given the high occurrence of coumarins in this genus, which exhibit potential anti-Alzheimer and anti-microbial properties, it presents promising new therapeutic avenues for addressing these common issues. Further investigation is needed to understand the molecular-level mechanisms of action and to explore their clinical applications.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":" ","pages":"825-899"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in artificial intelligence-based technologies for increasing the quality of medical products.","authors":"Nidhi Srivastava, Sneha Verma, Anupama Singh, Pranki Shukla, Yashvardhan Singh, Ankit D Oza, Tanvir Kaur, Sohini Chowdhury, Monit Kapoor, Ajar Nath Yadav","doi":"10.1007/s40199-024-00548-5","DOIUrl":"10.1007/s40199-024-00548-5","url":null,"abstract":"<p><p>Artificial intelligence (AI) is a technology that combines machine learning (ML) and deep learning. It has numerous usages in the domains of medicine and other sciences. Artificial intelligence can forecast the behavior of a drug's target protein and predict its desired physicochemical qualities. AI's potential to enhance healthcare services offerings formerly unheard-of opportunities for cost reserves, enhanced overall clinical and patient outcomes. The recent development of research in the biomedical field, encompassing fields such as genomics, computational medicine, AI, and algorithms for learning, has led to the demand for novel technology, a fresh workforce, and new standards of practice set the stage for the revolution in healthcare. By connecting these health statistics with cutting-edge AI technologies, precise insights into patient treatment can be obtained. Moreover, AI can aid in the search for new drugs by foretelling the target protein's two-dimensional structure. In the current review, an overview of the latest AI-based technologies and how they may be employed to reduce product development time to market and snowballing product quality, cost-effectiveness, as well as security throughout the manufacturing process is detailed.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"33 1","pages":"1"},"PeriodicalIF":2.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic role of erythropoietin in methanol induced optic neuropathy: a systematic review.","authors":"Neda Feizi, Mahsa Mohamadzadeh-Nabiei, Hadi Vahedi, Shadi Farabi Maleki, Ali Jafarizadeh","doi":"10.1007/s40199-024-00551-w","DOIUrl":"10.1007/s40199-024-00551-w","url":null,"abstract":"<p><strong>Purpose: </strong>Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION.</p><p><strong>Method: </strong>We systematically searched English and Persian databases including PubMed, Scopus, Embase, Web of Science, and Scientific Information Database (SID) as of July 2024. Two independent authors screened the articles based on their titles, abstracts, and full texts to finalize the included articles in this study. The selected articles underwent quality assessments via the Joanna Briggs Institute (JBI) checklists.</p><p><strong>Results: </strong>Out of 139 studies identified in the databases, 11 were finally included in the analysis. These studies encompassed 212 participants, with 192 receiving erythropoietin treatment. Visual acuity (VA) improved in 184 patients, with improvements ranging from no light perception to full vision recovery, or minor enhancements such as an improvement from 1.75 ± 0.72 to 1.32 ± 0.79 LogMAR. Only 8 patients showed no change or experienced deterioration. Additionally, 21 cases exhibited a reduction in retinal nerve fiber layer thickness, with one showing a reduction towards the normal range.</p><p><strong>Conclusion: </strong>This review highlights erythropoietin's positive impact on VA in patients with MION. However, simultaneous use of erythropoietin and corticosteroids in studies without control groups complicates evaluating erythropoietin's independent efficacy. Future research should involve large, controlled trials to clarify erythropoietin's role and establish it as a standard treatment.</p><p><strong>Prospero registration number: </strong>CRD42023485772.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"33 1","pages":"2"},"PeriodicalIF":2.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active pharmaceutical contaminants in drinking water: myth or fact?","authors":"Zvanaka Mazhandu, Tebogo Mashifana","doi":"10.1007/s40199-024-00536-9","DOIUrl":"https://doi.org/10.1007/s40199-024-00536-9","url":null,"abstract":"&lt;p&gt;Global water availability has been affected by a variety of factors, including climate change, water pollution, urbanization, and population growth. These issues have been particularly acute in many parts of the world, where access to clean water remains a significant challenge. In this context, preserving existing water bodies is a critical priority. Numerous studies have demonstrated the inadequacy of conventional water treatment processes in removing active pharmaceutical ingredients (APIs) from the water. These pharmaceutical active compounds have been detected in treated wastewater, groundwater, and even drinking water sources. The presence of APIs in water resources poses a significant threat not only to aquatic organisms but also to human health. These emerging contaminants have the potential to disrupt endocrine systems, promote the development of antibiotic-resistant bacteria, and bioaccumulate in the food chain, ultimately leading to unacceptable risks to public health. The inability of current conventional treatment methods to effectively remove APIs from water has raised serious concerns about the safety and reliability of water supplies. This issue requires immediate attention and the development of more effective treatment technologies to safeguard the quality of water resources and protect both aquatic ecosystems and human health. Other treatment methods, such as nanotechnology, microalgal treatment, and reverse osmosis, are promising in addressing the issue of API contamination in water resources. These innovative approaches have demonstrated higher removal efficiencies for a wide range of APIs compared to conventional methods, such as activated sludge and chlorination, which have been found to be inadequate in the removal of these emerging contaminants. The potential of these alternative treatment technologies to serve as effective tertiary treatment. To address this critical challenge, governments and policymakers should prioritize investment in research and development to establish effective and scalable solutions for eliminating APIs from various water sources. This should include comprehensive studies to assess the performance, cost-effectiveness, and environmental sustainability of emerging treatment technologies. The emerging contaminants should be included in robust water quality monitoring programs (Aus der Beek et al. in Environ Toxicol Chem 2016;35(4):823-835), with strict regulatory limits enforced to protect public health and the environment. By doing so, the scientific community and regulatory authorities can work together to develop a multi-barrier approach to safeguarding the water resources and ensuring access to safe, clean water for all. This review explores the potential of alternative treatment technologies to serve as viable solutions in the fight against API contamination. Innovative approaches, including nanotechnology, microalgal treatment, and reverse osmosis, have demonstrated remarkable success in ad","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"56 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure based exploration of mitochondrial alpha carbonic anhydrase inhibitors as potential leads for anti-obesity drug development","authors":"Ipsa Padhy, Tripti Sharma, Biswajit Banerjee, Sujata Mohapatra, Chita R. Sahoo, Rabindra Nath Padhy","doi":"10.1007/s40199-024-00535-w","DOIUrl":"https://doi.org/10.1007/s40199-024-00535-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Obesity has emerged as a major health challenge globally in the last two decades. Dysregulated fatty acid metabolism and <i>de novo</i> lipogenesis are prime causes for obesity development which ultimately trigger other co-morbid pathological conditions thereby risking life longevity. Fatty acid metabolism and <i>de novo</i> lipogenesis involve several biochemical steps both in cytosol and mitochondria. Reportedly, the high catalytically active mitochondrial carbonic anhydrases (CAVA/CAVB) regulate the intercellular depot of bicarbonate ions and catalyze the rapid carboxylation of pyruvate and acetyl-co-A to acetyl-co-A and malonate respectively, which are the precursors of fatty acid synthesis and lipogenesis. Several in vitro and in vivo investigations indicate inhibition of mitochondrial carbonic anhydrase isoforms interfere in the functioning of pyruvate, fatty acid and succinate pathways. Targeting of mitochondrial carbonic anhydrase isoforms (CAVA/CAVB) could thereby modulate gluconeogenetic as well as lipogenetic pathways and pave way for designing of novel leads in the development pipeline of anti-obesity medications.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The present review unveils a diverse chemical space including synthetic sulphonamides, sulphamates, sulfamides and many natural bioactive molecules which selectively inhibit the mitochondrial isoform CAVA/CAVB with an emphasis on major state-of-art drug design strategies.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>More than 60% similarity in the structural framework of the carbonic anhydrase isoforms has converged the drug design methods towards the development of isoform selective chemotypes. While the benzene sulphonamide derivatives selectively inhibit CAVA/CAVB in low nanomolar ranges depending on the substitutions on the phenyl ring, the sulpamates and sulpamides potently inhibit CAVB. The virtual screening and drug repurposing methods have also explored many non-sulphonamide chemical scaffolds which can potently inhibit CAVA.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The review could pave way for the development of novel and effective anti-obesity drugs which can modulate the energy metabolism.</p><h3 data-test=\"abstract-sub-heading\">Graphical abstract</h3>\u0000","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"29 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking cessation pharmacotherapy; varenicline or bupropion?","authors":"Fatemeh Rahimi, Ali Massoudifar, Roya Rahimi","doi":"10.1007/s40199-024-00539-6","DOIUrl":"https://doi.org/10.1007/s40199-024-00539-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>Tobacco smoking is a worldwide health problem and one of the leading causes of premature deaths in last years. As there are lots of researches focusing on cessation strategies with attention to pharmacotherapy and behavioral counseling, the aim of this study was to compare two of the first-line FDA-approved pharmacotherapies for smoking cessation; varenicline and bupropion.</p><h3 data-test=\"abstract-sub-heading\">Evidence acqusition</h3><p>This writing is an overview of researches published in Pubmed database from 2012 to 2022 with “Varenicline” and “Bupropion” as key words. Among the researches that were found, 24 articles were selected which mainly focused on comparison of these two medicines.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Varenicline and bupropion are known as non-nicotinic pharmacotherapy and have been used in addition to nicotine replacement therapy for smoking cessation. Varenicline is partial agonist for α4β2 nicotinic acetyl choline receptors while bupropion, classified as an atypical antidepressant, is actually a norepinephrine and dopamine reuptake inhibitor. Although these treatments can result in some adverse effects including nausea, insomnia, anxiety, irritability, fatigue and abnormal dreams, their efficacy in reduction of craving and also maintenance of abstinence is well been studied and approved by FDA. Moreover, adverse effects are usually mild to moderate clinical symptoms which can be tolerated and also easily managed and prevented in cases.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The efficacy and tolerability of varenicline and bupropion as treatments for smoking cessation is well understood. However, studies have shown that varenicline seems to be more effective in maintaining of abstinence and also reducing craving than bupropion and NRT.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"305 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}